Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

7.820 -0.120 (-1.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,299,554
Open 8.030
Bid (Size) 7.200 (50)
Ask (Size) 8.350 (4)
Prev. Close 7.940
Today's Range 7.760 - 8.030
52wk Range 6.290 - 9.475
Shares Outstanding 1,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook. 
Via Benzinga

Performance

YTD
+0.8%
+0.8%
1 Month
+8.8%
+8.8%
3 Month
-12.0%
-12.0%
6 Month
+0.4%
+0.4%
1 Year
+17.6%
+17.6%

More News

Read More
3 of Wall Street’s Favorite Stocks in the Doghouse
Via StockStory
Topics Intellectual Property
Exposures Intellectual Property
Amneal Recalls Three Lots Of UTI Drug Over Concerns of Microbial Contamination: Retail Sticks To Bearish Territory
Via Stocktwits
Topics Artificial Intelligence Product Recall
Exposures Artificial Intelligence Legal Product Safety
Amneal to Participate at Upcoming Investor Conferences in June
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress
Via StockStory
Topics Supply Chain
Exposures Supply Chain
Amneal Gets FDA Nod For Self-Administrable Migraine Injection
Via Stocktwits
Topics Data Breach
Exposures Information Security Product Safety
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
3 Russell 2000 Stocks in Hot Water
Via StockStory
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
3 Value Stocks in Hot Water
Via StockStory
Topics Supply Chain
Exposures Supply Chain
3 Small-Cap Stocks Facing Headwinds
Via StockStory
Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed
Via Benzinga
Amneal (NASDAQ:AMRX) Misses Q1 Sales Targets, Stock Drops 11.3%
Via StockStory
Amneal Reports First Quarter 2025 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For May 2, 2025
Via Benzinga
Examining the Future: Amneal Pharmaceuticals's Earnings Outlook
Via Benzinga
Amneal (AMRX) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
3 Profitable Stocks Skating on Thin Ice
Via StockStory
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
2 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Via StockStory
Topics Economy Government Stocks
Exposures Economy Political Tariff
3 of Wall Street’s Favorite Stocks That Concern Us
Via StockStory
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report First Quarter 2025 Results on May 2, 2025
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients
Via Benzinga

Frequently Asked Questions

Is Amneal Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Amneal Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Amneal Pharmaceuticals, Inc. - Class A Common Stock trade on?
Amneal Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock is AMRX on the Nasdaq Stock Market
What is the current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 7.820
When was Amneal Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Amneal Pharmaceuticals, Inc. - Class A Common Stock was at 06/20/25 04:00 PM ET
What is the market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 7.82K
How many shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Amneal Pharmaceuticals, Inc. - Class A Common Stock has 8K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.